Huakang Biomedical Holdings Company Limited (8622.HK)
HKD 0.18
(1.67%)
HKD 0.18
(1.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.55 Million CNY | -1456.38% |
| 2022 | 188 Thousand CNY | 122.07% |
| 2021 | -852 Thousand CNY | 84.64% |
| 2020 | -8.1 Million CNY | -271.66% |
| 2019 | 3.49 Million CNY | -24.73% |
| 2018 | 4.29 Million CNY | 249.39% |
| 2017 | 1.22 Million CNY | -89.98% |
| 2016 | 12.26 Million CNY | 11.62% |
| 2015 | 10.99 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -699 Thousand CNY | 78.56% |
| 2024 Q2 | -699 Thousand CNY | 0.0% |
| 2023 Q2 | -933 Thousand CNY | -106.87% |
| 2023 Q4 | -3.26 Million CNY | -302.1% |
| 2023 Q1 | -451 Thousand CNY | 84.16% |
| 2023 Q3 | -811 Thousand CNY | 13.08% |
| 2023 FY | - CNY | -1456.38% |
| 2022 Q2 | -150 Thousand CNY | 74.87% |
| 2022 Q1 | -597 Thousand CNY | 75.61% |
| 2022 FY | - CNY | 122.07% |
| 2022 Q3 | 859 Thousand CNY | 672.67% |
| 2022 Q4 | -2.84 Million CNY | -431.43% |
| 2021 Q4 | -2.44 Million CNY | -971.17% |
| 2021 FY | - CNY | 84.64% |
| 2021 Q3 | 281 Thousand CNY | 146.29% |
| 2021 Q2 | -607 Thousand CNY | 40.9% |
| 2021 Q1 | -1.02 Million CNY | 68.03% |
| 2020 Q4 | -3.21 Million CNY | -5080.65% |
| 2020 Q3 | -62 Thousand CNY | 98.14% |
| 2020 Q2 | -3.34 Million CNY | -56.95% |
| 2020 Q1 | -2.12 Million CNY | -1966.02% |
| 2020 FY | - CNY | -271.66% |
| 2019 Q4 | -103 Thousand CNY | -112.42% |
| 2019 Q3 | 829 Thousand CNY | 131.56% |
| 2019 Q2 | 358 Thousand CNY | 157.28% |
| 2019 FY | - CNY | -24.73% |
| 2019 Q1 | -625 Thousand CNY | 71.85% |
| 2018 Q3 | 2.4 Million CNY | 0.67% |
| 2018 Q4 | -2.22 Million CNY | -192.38% |
| 2018 FY | - CNY | 249.39% |
| 2018 Q2 | 2.38 Million CNY | 10750.0% |
| 2018 Q1 | 22 Thousand CNY | 0.0% |
| 2017 FY | - CNY | -89.98% |
| 2016 FY | - CNY | 11.62% |
| 2015 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 101.695% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 100.086% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 98.031% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | 102.241% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 94.923% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | 102.322% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 100.609% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | 103.328% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 90.256% |
| SSY Group Limited | 2.11 Billion HKD | 100.121% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 101.248% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 100.593% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 100.017% |